Brokerages expect that Impax Laboratories Inc (NASDAQ:IPXL) will report $184.90 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Impax Laboratories’ earnings, with the highest sales estimate coming in at $198.88 million and the lowest estimate coming in at $172.43 million. Impax Laboratories posted sales of $184.40 million during the same quarter last year, which suggests a positive year-over-year growth rate of 0.3%. The firm is expected to report its next quarterly earnings report on Wednesday, May 9th.

According to Zacks, analysts expect that Impax Laboratories will report full-year sales of $184.90 million for the current year, with estimates ranging from $1.63 billion to $1.80 billion. For the next financial year, analysts forecast that the company will report sales of $2.23 billion per share, with estimates ranging from $2.09 billion to $2.32 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Impax Laboratories.

How to Become a New Pot Stock Millionaire

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.01). The firm had revenue of $182.90 million for the quarter, compared to the consensus estimate of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share.

IPXL has been the subject of a number of analyst reports. Cantor Fitzgerald set a $35.00 price target on Impax Laboratories and gave the company a “buy” rating in a research note on Friday, December 15th. Leerink Swann began coverage on Impax Laboratories in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 price objective for the company. BidaskClub cut Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 16th. Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Guggenheim began coverage on Impax Laboratories in a research report on Tuesday, December 12th. They issued a “neutral” rating and a $18.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $20.91.

Impax Laboratories stock traded down $0.60 during mid-day trading on Friday, reaching $20.45. The company’s stock had a trading volume of 497,688 shares, compared to its average volume of 1,015,466. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96. The company has a market capitalization of $1,556.36, a P/E ratio of -3.14, a price-to-earnings-growth ratio of 0.89 and a beta of 1.01. Impax Laboratories has a 12-month low of $8.80 and a 12-month high of $25.70.

A number of hedge funds and other institutional investors have recently made changes to their positions in IPXL. Xact Kapitalforvaltning AB bought a new position in shares of Impax Laboratories in the 4th quarter valued at $198,000. Envestnet Asset Management Inc. increased its stake in shares of Impax Laboratories by 470.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 20,581 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 16,976 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in shares of Impax Laboratories in the 4th quarter valued at $597,000. Element Capital Management LLC bought a new position in shares of Impax Laboratories in the 4th quarter valued at $2,463,000. Finally, Jane Street Group LLC bought a new stake in Impax Laboratories during the 4th quarter worth $1,004,000. 90.40% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “$184.90 Million in Sales Expected for Impax Laboratories Inc (IPXL) This Quarter” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2018/03/19/184-90-million-in-sales-expected-for-impax-laboratories-inc-ipxl-this-quarter.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Get a free copy of the Zacks research report on Impax Laboratories (IPXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.